FDA fully approves Pfizer new crown vaccine
The U.S. Food and Drug Administration (FDA) announced that it had fully approved Pfizer’s new crown vaccine. The three major stock indexes opened higher on Monday. Among them, the rise in the middle of the Dow index expanded to more than 300 points, and the peak of the standard index and the NASDAQ index broke through the intraday, with an increase of more than 1%.
The S & P 500 and the NASDAQ rose for three consecutive days, both reaching closing highs. As of the close, S & P rose 0.85% to 4479.56 points, the largest closing increase since July 23; The NASDAQ rose 1.55% to 14942.65 points, the largest closing gain since May 20; The Dow rose 215.63 points, or 0.61%, the largest increase since August 11, at the highest closing level in the last four trading days.
The US Food and Drug Administration (FDA) fully approved the new crown vaccine jointly developed by Pfizer and biontech on Monday. The formal approval of the vaccine applies to Americans over the age of 16, while the emergency use authorization is still valid for people aged 12 to 15. Pfizer vaccine became the first new crown vaccine to win this award. This has greatly improved the confidence of more enterprises, schools and colleges to vaccinate.
Pfizer’s new mRNA crown vaccine was granted emergency use right by FDA last December. According to the statistics of the Centers for Disease Control and Prevention (CDC), so far, more than 204 million doses of Pfizer vaccine have been put into use.
After the FDA announced that Pfizer’s new crown vaccine had been fully approved, the anti epidemic concept stocks rose on the same day. Biontech closed up nearly 9.6%, Novax rose more than 8.7%, mRNA. O rose more than 7.5%, curevac rose about 6.3%, vaxart rose more than 5.5%, Pfizer pharmaceutical rose about 2.5% and AstraZeneca fell about 1.0%.
The U.S. Food and Drug Administration said that before full approval, scientists evaluated “hundreds of thousands of pages” of vaccine data from 40000 trial participants. The effectiveness of the two dose vaccine in preventing COVID-19 is 91%, which is slightly lower than the 95% test data before the end of last year when the vaccine was approved and the delta variant was popular in the United States.
In addition, novel coronavirus pneumonia vaccine has no time to waste, said President Biden. States that have lagged behind in vaccination have improved. More companies must strengthen the requirements for employees to be vaccinated (and then return to the office). Please complete the vaccination today.
In the bond market, the yield of 10-year US bonds fell slightly to 1.253%, which rose to 1.282% in early European trading. The yield of 20-year US bonds rose 0.38 basis points to 1.7911%; The 30-year US Treasury yield fell 0.27 basis points to 1.8708%.
Investors will focus on this week’s central bank seminar in Jackson Hole, Wyoming, to find clues about when the Fed began to slow down its $120 billion monthly bond purchase. Federal Reserve Chairman Powell is scheduled to deliver a keynote speech at 10 a.m. Eastern time on Friday (August 27).